NEW YORK, Jan. 25, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM®Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, held its second annual board meeting on January 20, 2017 in New York City. AXIM Biotech board members reviewed company milestones in 2016, and discussed clinical trial progress for irritable bowel syndrome (IBS), multiple sclerosis (MS) and psoriasis and eczema (PSO) as well as additional R&D activities for the next 12 months. The meeting also approved budgets needed to carry out the clinical projects and business developments.
Management and advisory board experts considered further proof of concept studies of cannabis based treatment for indications such as nicotine addiction, Restless Leg Syndrome, postherpetic neuralgia, and drug related psychosis. Other items discussed during the board meeting included progress on vertical integration with the manufacturing facility in Almere, Netherland, use of natural versus synthetic cannabinoids and antibacterial preparations with CBG, CBD and halogenated metals.
“AXIM achieved exciting milestone developments in 2016,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “We are entering the New Year with a robust clinical pipeline in IBS, MS and PSO and expanded study for additional therapeutic indications. We are fortunate to have research collaboration with leading experts, and will continue to optimize our company structure to execute our business goals. With our patented delivery technology and broad research and product portfolio, AXIM is becoming a leader in the cannabis-based pharmaceutical space.”
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, please visit www.AXIMBiotech.com.
About CanChew® and CanChew Plus®
CanChew® is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew® website include:
No prescription needed
Available in all 50 states
Great-tasting mint gum has no artificial sweeteners or preservatives
Non-GMO, gluten free, vegan and kosher
CanChew Plus® is a vastly improved delivery system than the alpha version of CanChew® Gum. It is produced by a leading European functional gum manufacturer.
Featured in Healthy Living Magazine, CanChew® was also recognized by the HealthyLivinG Foundation and honored with its Triple Leaf Award.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
For the original press release, click here.